BTIG Reiterates Buy on Caris Life Sciences, Maintains $32 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 88.9%

Neg 0% Neu 88.9% Pos 0%

BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ:CAI) with a Buy and maintains $32 price target.

Comments

No comments yet. Be the first!